SIM0500
A Phase I First-in-human, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, A Humanized GPRC5D-BCMA-CD3 Tri-specific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
What will happen during the trial?
The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 130 patients (estimated)
- Sponsors
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Collaborators
- Shanghai Xianxiang Medical Technology Co., Ltd.
- Tags
- Trispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3, GPRC5D
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 2022
- NCT Identifier
- NCT06375044
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.